Remdesivir

Lenacapavir injections, administered twice yearly, reduced HIV infections by 96% in a gender-diverse population, according to study findings presented at the HIV Research for Prevention conference.

A combination of remdesivir plus dexamethasone significantly reduced the risk for death among people hospitalized with COVID-19 with baseline oxygen requirements compared with dexamethasone alone, according to a study.

Use of remdesivir in hospitalized patients with COVID-19 and reduced eGFR did not decrease the risk of major adverse cardiovascular events or major adverse kidney disease.

PHILADELPHIA — Remdesivir did not reduce adverse cardiovascular or kidney events in adults with underlying kidney damage hospitalized for COVID-19, a speaker here said.

Remdesivir use is associated with increased survival among patients hospitalized with COVID-19 requiring supplemental oxygen, researchers found.

If given to patients with early and symptomatic COVID-19, treatment with remdesivir can accelerate the rate of viral clearance in oropharyngeal swabs over 1 week, researchers found.

NASHVILLE, Tenn. — Combination therapy with remdesivir and dexamethasone plus tocilizumab yielded reductions in inflammatory markers and mortality and more discharges for patients with COVID-19 hospitalized in the ICU, researchers reported.

Remdesivir treatment reduced risks for mortality, high-flow nasal cannula use and transfer to the ICU among patients on hemodialysis hospitalized with COVID-19, according to a study in Kidney International Reports.

Despite a lower overall mortality rate, lung transplant recipients remain at high risk for severe disease and death from the COVID-19 omicron variant compared with both the general population and other respiratory infections.

The FDA has approved Veklury for pediatric patients aged 28 days and older who are hospitalized for COVID-19 or have mild to moderate COVID-19 and are at risk for severe disease.